Aurobindo Pharma submits ANDA for Empagliflozin and Metformin Hydrochloride
Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for Empagliflozin and Metformin Hydrochloride.
Asset / Drug
Drug and asset intelligence for Empagliflozin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor and Biguanide
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.